Lexeo Therapeutics (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 3,342 Shares

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 3,342 shares of Lexeo Therapeutics stock in a transaction on Monday, May 18th. The stock was sold at an average price of $5.06, for a total transaction of $16,910.52. Following the sale, the chief executive officer owned 336,764 shares of the company’s stock, valued at $1,704,025.84. The trade was a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Richard Nolan Townsend also recently made the following trade(s):

• On Monday, April 6th, Richard Nolan Townsend sold 55,000 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $5.69, for a total transaction of $312,950.00.

Lexeo Therapeutics Trading Up 14.3%

NASDAQ:LXEO opened at $5.12 on Thursday. Lexeo Therapeutics, Inc. has a 12 month low of $2.51 and a 12 month high of $10.99. The firm has a fifty day simple moving average of $5.96 and a 200-day simple moving average of $7.56. The company has a market capitalization of $402.02 million, a P/E ratio of -3.53 and a beta of 1.52.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its earnings results on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Equities analysts forecast that Lexeo Therapeutics, Inc. will post -1.19 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on LXEO. Chardan Capital restated a “buy” rating and set a $17.00 target price on shares of Lexeo Therapeutics in a research report on Monday, May 11th. Weiss Ratings upgraded shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 15th. Finally, Wall Street Zen upgraded shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Lexeo Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $18.88.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE increased its holdings in Lexeo Therapeutics by 206.7% in the first quarter. Bank of America Corp DE now owns 491,532 shares of the company’s stock valued at $2,821,000 after buying an additional 331,244 shares in the last quarter. ADAR1 Capital Management LLC increased its stake in shares of Lexeo Therapeutics by 5.3% during the first quarter. ADAR1 Capital Management LLC now owns 1,467,350 shares of the company’s stock worth $8,423,000 after purchasing an additional 74,189 shares in the last quarter. Orbimed Advisors LLC increased its stake in shares of Lexeo Therapeutics by 69.5% during the first quarter. Orbimed Advisors LLC now owns 3,602,450 shares of the company’s stock worth $20,678,000 after purchasing an additional 1,477,450 shares in the last quarter. Affinity Asset Advisors LLC increased its stake in shares of Lexeo Therapeutics by 57.8% during the first quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company’s stock worth $28,988,000 after purchasing an additional 1,850,211 shares in the last quarter. Finally, Spruce Street Capital LP increased its stake in shares of Lexeo Therapeutics by 430.6% during the first quarter. Spruce Street Capital LP now owns 928,593 shares of the company’s stock worth $5,330,000 after purchasing an additional 753,593 shares in the last quarter. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.